Alexianer St Joseph Berlin-Weissensee GmbH
- Address
- Gartenstrasse 1, Weissensee, 13088 Berlin, Germany
Alexianer St Joseph Berlin-Weissensee GmbH - Neurological Research Center
Alexianer St Joseph Berlin-Weissensee GmbH is a clinical research facility specializing in neurological disorders, with particular expertise in the investigation and treatment of relapsing multiple sclerosis (RMS). The center focuses on evaluating novel therapeutic approaches for patients with newly diagnosed autoimmune neurological conditions, contributing to the advancement of disease-modifying treatment strategies.
- Comparative efficacy studies of disease-modifying therapies for multiple sclerosis
- First-line treatment evaluation in treatment-naïve RMS patients
- Safety and tolerability assessment of novel immunotherapeutic agents
The research center demonstrates commitment to optimizing treatment outcomes for patients at the earliest stages of their disease course, conducting rigorous trials that compare innovative biological therapies with established first-line treatments. Their work plays a crucial role in defining optimal therapeutic strategies for newly diagnosed RMS patients, helping to establish evidence-based guidelines for initial disease management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Biohaven Therapeutics Ltd.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Alexianer St Joseph Berlin-Weissensee GmbH
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants with Early Parkinson’s Disease | Biohaven Therapeutics Ltd. | Phase IV | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dimethyl Fumarate | 1 | Unknown | 2021-07-23 | 2021-07-23 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.